Mark  Pomeranz net worth and biography

Mark Pomeranz Biography and Net Worth

COO of Motus GI
Mr. Pomeranz has served as Chief Operating Officer since September 24, 2018. Prior to his tenure as our Chief Operating Officer, Mr. Pomeranz served as our Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform in the EU. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. Mr. Pomeranz was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd. and his business and leadership experience in the medical technology sector; his broad scientific background is also seen as an asset to us.

How old is Mark Pomeranz?

Mr. Pomeranz is currently 62 years old. There are 2 older executives and no younger executives at Motus GI. Learn More on Mark Pomeranz's age.

How do I contact Mark Pomeranz?

The corporate mailing address for Mr. Pomeranz and other Motus GI executives is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. Motus GI can also be reached via phone at (954) 541-8000 and via email at [email protected]. Learn More on Mark Pomeranz's contact information.

Has Mark Pomeranz been buying or selling shares of Motus GI?

Mark Pomeranz has not been actively trading shares of Motus GI during the last quarter. Most recently, on Friday, November 19th, Mark Pomeranz bought 266 shares of Motus GI stock. The stock was acquired at an average cost of $7.65 per share, with a total value of $2,034.90. Learn More on Mark Pomeranz's trading history.

Who are Motus GI's active insiders?

Motus GI's insider roster includes Timothy Moran (CEO), Mark Pomeranz (COO), and Andrew Taylor (CFO). Learn More on Motus GI's active insiders.

Mark Pomeranz Insider Trading History at Motus GI

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy266$7.65$2,034.90View SEC Filing Icon  
7/1/2019Buy66$45.00$2,970.00View SEC Filing Icon  
12/24/2018Buy166$40.50$6,723.00View SEC Filing Icon  
2/16/2018Buy533$75.00$39,975.00View SEC Filing Icon  
See Full Table

Mark Pomeranz Buying and Selling Activity at Motus GI

This chart shows Mark Pomeranz's buying and selling at Motus GI by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Motus GI Company Overview

Motus GI logo
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: $0.02
Low: $0.00
High: $0.05

2 Week Range

Now: $0.00
Low: $0.00
High: $5.67

Volume

2,816 shs

Average Volume

580,188 shs

Market Capitalization

$2,308.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93